RU2167160C2 - Производные 5-фенил-3-(пиперидин-4-ил)-1,3,4-оксадиазол-2(3н)-она, способ их получения, фармацевтическая композиция на их основе и лекарственное средство - Google Patents

Производные 5-фенил-3-(пиперидин-4-ил)-1,3,4-оксадиазол-2(3н)-она, способ их получения, фармацевтическая композиция на их основе и лекарственное средство Download PDF

Info

Publication number
RU2167160C2
RU2167160C2 RU98110976/04A RU98110976A RU2167160C2 RU 2167160 C2 RU2167160 C2 RU 2167160C2 RU 98110976/04 A RU98110976/04 A RU 98110976/04A RU 98110976 A RU98110976 A RU 98110976A RU 2167160 C2 RU2167160 C2 RU 2167160C2
Authority
RU
Russia
Prior art keywords
group
piperidin
dihydro
general formula
dimethylamino
Prior art date
Application number
RU98110976/04A
Other languages
English (en)
Russian (ru)
Other versions
RU98110976A (ru
Inventor
Самир ЖЕГАМ (FR)
Самир Жегам
Алистер ЛОКХЕД (FR)
Алистер Локхед
Фредерик ГАЛЛИ (FR)
Фредерик Галли
Ален НЕДЕЛЕК (FR)
Ален Неделек
Аксель СОЛИНЬЯК (FR)
Аксель Солиньяк
КРЮ Лоранс ДЕ (FR)
Крю Лоранс Де
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of RU98110976A publication Critical patent/RU98110976A/ru
Application granted granted Critical
Publication of RU2167160C2 publication Critical patent/RU2167160C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU98110976/04A 1995-11-09 1996-11-05 Производные 5-фенил-3-(пиперидин-4-ил)-1,3,4-оксадиазол-2(3н)-она, способ их получения, фармацевтическая композиция на их основе и лекарственное средство RU2167160C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR95/13253 1995-11-09
FR95/13252 1995-11-09
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
FR96/02663 1996-03-04

Publications (2)

Publication Number Publication Date
RU98110976A RU98110976A (ru) 2000-10-10
RU2167160C2 true RU2167160C2 (ru) 2001-05-20

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98110976/04A RU2167160C2 (ru) 1995-11-09 1996-11-05 Производные 5-фенил-3-(пиперидин-4-ил)-1,3,4-оксадиазол-2(3н)-она, способ их получения, фармацевтическая композиция на их основе и лекарственное средство

Country Status (29)

Country Link
US (1) US5929089A (enExample)
EP (1) EP0863897B1 (enExample)
JP (1) JP4263240B2 (enExample)
CN (1) CN1077891C (enExample)
AR (1) AR004708A1 (enExample)
AT (1) ATE181328T1 (enExample)
AU (1) AU707325B2 (enExample)
BG (1) BG63463B1 (enExample)
BR (1) BR9611311A (enExample)
CA (1) CA2236357C (enExample)
CO (1) CO4770968A1 (enExample)
CZ (1) CZ287268B6 (enExample)
DE (1) DE69602970T2 (enExample)
EE (1) EE03487B1 (enExample)
ES (1) ES2135934T3 (enExample)
GR (1) GR3030823T3 (enExample)
HU (1) HUP0001168A3 (enExample)
IL (1) IL124364A (enExample)
MX (1) MX9803696A (enExample)
NO (1) NO309606B1 (enExample)
NZ (1) NZ321626A (enExample)
PL (1) PL186204B1 (enExample)
RU (1) RU2167160C2 (enExample)
SI (1) SI0863897T1 (enExample)
SK (1) SK282335B6 (enExample)
TR (1) TR199800827T2 (enExample)
TW (1) TW371303B (enExample)
UA (1) UA50748C2 (enExample)
WO (1) WO1997017345A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2360902C2 (ru) * 2003-11-06 2009-07-10 Аддекс Фарма Са Аллостерические модуляторы метаботропных глутаматных рецепторов
RU2396269C2 (ru) * 2005-12-01 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
WO1998050383A1 (fr) * 1997-05-06 1998-11-12 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
AU755119B2 (en) 1998-09-18 2002-12-05 Alcon Laboratories, Inc. Serotonergic 5HT2 agonists for treating glaucoma
WO2000064441A2 (en) * 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
US6638967B2 (en) 2000-08-08 2003-10-28 Ortho-Mcneil Phamraceutical, Inc. Thiophene of furan pyrrolidine compounds
CA2418369A1 (en) 2000-08-08 2002-02-14 Richard Apodaca Non-imidazole aryloxyalkylamines as h3 receptor ligands
CZ2003686A3 (cs) * 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical, Inc. Neimidazolové aryloxypiperidiny
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
EP1434765B1 (en) * 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
JP2005511764A (ja) 2001-12-14 2005-04-28 アルコン，インコーポレイテッド 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
EA200801607A1 (ru) 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
CN103110635A (zh) * 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
ATE538116T1 (de) * 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
DK2758394T3 (en) * 2011-09-19 2015-04-20 Suven Life Sciences Ltd HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012561C1 (ru) * 1990-08-13 1994-05-15 Хехст-Рассел Фармасьютикалз Инкорпорейтед 3-(1,2-бензизоксазол-3-ил)-4-пиридамины, проявляющие анальгетическую, антихолинэстеразную и дерматологическую активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243993A (en) * 1991-08-20 1994-10-26 Smithkline Beecham Plc Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
ES2135414T3 (es) * 1991-09-12 1999-11-01 Smithkline Beecham Plc Antagonistas del receptor 5-ht4.
CA2129112A1 (en) * 1992-02-06 1993-08-19 Francis David King Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012561C1 (ru) * 1990-08-13 1994-05-15 Хехст-Рассел Фармасьютикалз Инкорпорейтед 3-(1,2-бензизоксазол-3-ил)-4-пиридамины, проявляющие анальгетическую, антихолинэстеразную и дерматологическую активность

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2360902C2 (ru) * 2003-11-06 2009-07-10 Аддекс Фарма Са Аллостерические модуляторы метаботропных глутаматных рецепторов
RU2396269C2 (ru) * 2005-12-01 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)

Also Published As

Publication number Publication date
BG63463B1 (bg) 2002-02-28
AR004708A1 (es) 1999-03-10
TW371303B (en) 1999-10-01
CN1202169A (zh) 1998-12-16
AU7500196A (en) 1997-05-29
PL326671A1 (en) 1998-10-12
US5929089A (en) 1999-07-27
WO1997017345A1 (fr) 1997-05-15
CZ287268B6 (en) 2000-10-11
EE9800155A (et) 1998-12-15
HUP0001168A2 (hu) 2001-04-28
BG102412A (en) 1999-08-31
EP0863897A1 (fr) 1998-09-16
JP2000500125A (ja) 2000-01-11
DE69602970D1 (de) 1999-07-22
HK1016165A1 (en) 1999-10-29
ES2135934T3 (es) 1999-11-01
MX9803696A (es) 1998-09-30
SK59998A3 (en) 1998-11-04
CN1077891C (zh) 2002-01-16
IL124364A0 (en) 1998-12-06
JP4263240B2 (ja) 2009-05-13
NO309606B1 (no) 2001-02-26
DE69602970T2 (de) 2000-01-20
IL124364A (en) 2001-08-08
UA50748C2 (uk) 2002-11-15
CZ142198A3 (cs) 1998-08-12
SI0863897T1 (en) 1999-10-31
NO982092L (no) 1998-06-29
NZ321626A (en) 1998-10-28
HUP0001168A3 (en) 2001-07-30
NO982092D0 (no) 1998-05-07
EE03487B1 (et) 2001-08-15
EP0863897B1 (fr) 1999-06-16
BR9611311A (pt) 1999-06-29
PL186204B1 (pl) 2003-11-28
ATE181328T1 (de) 1999-07-15
SK282335B6 (sk) 2002-01-07
GR3030823T3 (en) 1999-11-30
AU707325B2 (en) 1999-07-08
TR199800827T2 (xx) 1999-02-22
CO4770968A1 (es) 1999-04-30
CA2236357C (en) 2006-10-17
CA2236357A1 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
US5929089A (en) 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-Ht4 or H3 receptor ligands
CZ333094A3 (en) Morpholine and thiomorpholine derivatives, process of their preparation and pharmaceutical composition containing thereof
TW201311674A (zh) 吲唑－及吡咯并吡啶－衍生物及其醫藥用途
RU2186066C2 (ru) Производные 5-арил-3-(8-азабицикло[3.2.1]окт-3-ил)-1,3,4-оксадиазол-2(3h)-она, способ их получения, лекарственное средство и фармацевтическая композиция
JPH06157518A (ja) 新規なオキサジアゾール誘導体又はその塩
KR100474454B1 (ko) 5-ht₄또는h₃수용체리간드로서사용하기위한5-페닐-3-(피페리딘-4-일)-1,3,4-옥사디아졸-2(3h)-온유도체
US6248757B1 (en) 3-(Pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives and their use as 5-HT4 ligands
HK1016165B (en) 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands
FR2741070A1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR2741069A1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR2745574A1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
FR2763067A1 (fr) Derives de 3-(1-azabicyclo[2.2.2] oct-3-ylalkyl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
EP0980370A1 (fr) Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
MXPA99009506A (en) 5-aryl-3-(8-azabicyclo(3.2.2)oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives as 5-ht4 receptor ligands
JPH11508536A (ja) アドレナリン性α▲下１ａ▼受容体アンタゴニスト
FR2759699A1 (fr) Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20131106